Patients are at the center of everything we do at GlycoMimetics. Through collaboration with our clinical partners, we are conducting clinical studies that explore the use of product candidates developed by our scientists in multiple oncology and other indications. Our central goal is to obtain the data required for review and approval by regulatory authorities, such as the U.S. Food and Drug Administration.
- Uproleselan (GMI-1271): This ongoing pivotal Phase 3 trial (NCT03616470) plans to enroll 380 patients ages 18 to 75 with relapsed/refractory acute myeloid leukemia who are considered to be medically eligible to receive intensive chemotherapy.
- Uproleselan (GMI-1271) is being evaluated by a consortium of the National Cancer Institute as a potential new treatment for newly diagnosed AML patients fit for chemotherapy. This is an ongoing effort with multiple sites across the U.S. participating.
- Rivipansel: In August 2019, Pfizer reported disappointing results from the Phase 3 RESET trial (NCT02187003) after it failed to meet the primary endpoint of the study. A post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel in acute vaso-occlusive crisis (VOC) showed that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placebo. In addition, biomarker data showed reductions in soluble E-selectin confirming that rivipansel hit its intended biological target. GycoMimetics believes that these findings confirm the critical role of E-selectin in acute vaso-occlusion, as well as the importance of treating individuals early in the course of their acute painful crisis. These data are contained in abstracts published online (see page 26) in June 2020 and were presented at the September 23-25 meeting of the Foundation for Sickle Cell Disease Research (FSCDR) as well as at the Annual Meeting of the American Society of Hematology (ASH) in December 2020. We are committed to discussing these data with the U.S. Food and Drug Administration (FDA) as well as consulting with KOLs to determine what, if any, next steps could be taken to carry this GlycoMimetics wholly-owned development program forward in acute VOC, either in pediatrics or in the overall population.
To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov. ClinicalTrials.gov is a registry of publicly and privately supported clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidate’s name (e.g., uproleselan).